ClinicalTrials.gg
Not yet recruitingNCT07620795Updated Sep 22, 2026

Effect of Web-Based Education on Attitudes and Beliefs About HPV Testing

An interventional study of Web-Based Health Education in Cervical Cancer and HPV, sponsored by Sakarya University. Not yet recruiting. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Sakarya University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

Cervical cancer is a highly preventable public health issue that significantly impacts women's quality of life. Although effective screening programs such as Human Papilloma Virus (HPV) testing and Pap-smears are widely available, women's participation in these early detection services often remains limited. The primary barriers to screening attendance include insufficient education, lack of information, negative beliefs, psychosocial or cultural factors, and misconceptions regarding gynecological examinations. To improve screening uptake, health interventions must focus not only on increasing knowledge but also on promoting correct beliefs and positive attitudes toward testing.

Web-based health education serves as an effective method to overcome barriers such as cost, transportation difficulties, and geographical limitations, allowing wider access to healthcare guidance. This study aims to evaluate the effects of a specialized web-based educational intervention on women's attitudes and beliefs regarding the HPV test. The research is designed as a randomized controlled trial with a pre-test and post-test design. Participants will be assigned to either an intervention group or a control group. The intervention group will receive structured health education through a dedicated web platform, while the control group will receive routine standard follow-up. Data will be gathered using a specific attitude and belief scale before and after the application to measure the intervention's impact.

02

Conditions studied

  • Cervical Cancer
  • HPV

Keywords

  • HPV Testing
  • Health Education
  • Web-based learning
  • Attitudes and Beliefs
03

In context

Uterine Cervical Neoplasms

2,366 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.

This study's planned enrollment of 120 is above the median of 100 across 1,738 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Sakarya University is the lead sponsor of 190 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having no prior clinical diagnosis of cervical cancer
  • Being between 18 and 60 years of age
  • Having active access to the internet
  • Being literate at a level sufficient to read and understand the questionnaire forms
  • Being capable of effectively navigating and using a web browser
  • Being registered as a patient at Sakarya Akyazı No. 3 Family Health Center
  • Volunteering to participate in the study and providing

Exclusion criteria

Exclusion Criteria:

  • Withdrawing from the study voluntarily at any stage
  • Failing to watch the mandatory educational videos on the platform
  • Submitting incomplete or incorrect responses to the data collection tools
  • Lacking active internet access or proper web browser usage skills

Criteria for Study Discontinuation / Drop-out:

  • Participant's request to withdraw from the study
  • Failure to respond to or complete the data collection tools
  • Not using or logging into the web application for more than 2 consecutive weeks during the study period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants in this group will receive access to the web-based health education platform developed for the study.

    Behavioral: Web-Based Health Education

  • No intervention
    control group

    Participants in this group will receive standard routine follow-up during the study. After the completion of the study data collection, the web-based health education platform will also be made accessible to this group.

Interventions

  • BehavioralWeb-Based Health Education

    Participants in the intervention group will receive health education through a specially designed web-based platform containing 11 presentations in total (8 PowerPoint presentations, 1 animation video explaining how the HPV test is performed, and 1 researcher-led instructional video demonstrating self-vulvar examination on a model). Participants will also be provided with educational brochures and magnets. For participants who do not view the presentations, weekly reminder text messages will be sent to encourage platform login and module completion.

06

What researchers measure

Primary outcomes

  1. Attitudes and Beliefs About HPV Testing Scale (ABHTS) - Personal Barriers Subscale

    This subscale consists of 7 items (items 1-7) assessing personal barriers, stigma, and shame related to HPV testing. Scores range from 7 to 49. A higher score indicates a higher level of perceived personal barriers, meaning a less favorable attitude toward HPV testing.

    Time frame: Baseline and 12 weeks post-intervention

  2. Attitudes and Beliefs About HPV Testing Scale (ABHTS) - Social Norms Subscale

    This subscale consists of 4 items (items 8-11) assessing the influence of friends, partners, family, and social media on HPV testing. Scores range from 4 to 28. A higher score indicates higher negative social pressure/barriers, meaning a lower level of favorable attitudes and beliefs

    Time frame: Baseline and 12 weeks post-intervention

  3. Attitudes and Beliefs About HPV Testing Scale (ABHTS) - Trust Subscale

    This subscale consists of 6 items (items 12-17) assessing trust in the healthcare system, accuracy of HPV testing, and medical procedures. Scores range from 6 to 42. A higher score indicates higher levels of perceived benefit, confidence, and trust toward HPV testing.

    Time frame: Baseline and 12 weeks post-intervention

  4. Attitudes and Beliefs About HPV Testing Scale (ABHTS) - Concerns Subscale

    This subscale consists of 3 items (items 18-20) assessing concerns and worries related to the process and outcomes of HPV testing. Scores range from 3 to 21. A higher score indicates higher levels of concerns/negative attitudes toward HPV testing.

    Time frame: Baseline and 12 weeks post-intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to ensure and maintain participant confidentiality in accordance with the institutional ethics committee approval and local data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Of 445 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 2 months is below that.

Counting every sponsor, half of 461 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 2, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07620795
Lead sponsor
Sakarya University
Responsible party
Merve Icoz (Phd Candidate, Department of Midwifery, Sakarya University) — Principal investigator
First posted
Jun 2, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Sep 22, 2026

Study contacts

MERVE İÇÖZ, Phd Student, Msc Midwife
Contact
merve.icoz@ogr.sakarya.edu.tr
+905072094020
ZEKİYE TURAN, Phd, Associate Professor
Contact
zekiyeturan@sakarya.edu.tr
+905055376788
ZEKİYE TURAN, Phd, Associate Professor
study chair · Sakarya University Faculty of Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion